FLT3-TKD Mutations Associated With NPM1 Mutations Define a Favorable-risk Group in Patients With Acute Myeloid Leukemia
Marielle Perry(Hospices Civils de Lyon), Étienne Paubelle(Centre Hospitalier Universitaire Amiens-Picardie), Christian Récher(Institut universitaire du cancer de Toulouse Oncopole), Sarah Bertoli(Memorial Sloan Kettering Cancer Center), Fiorenza Barraco(Hôpital Lyon Sud), Clément Rocher(Hospices Civils de Lyon), Xavier Thomas(Hôpital Lyon Sud), Hélène Labussière‐Wallet(Hospices Civils de Lyon), Gilles Salles(Memorial Sloan Kettering Cancer Center), Sandrine Hayette(Hôpital Claude Huriez), Sophie Ducastelle(Hôpital Lyon Sud)
Cited by 27
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k